Business
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Corbus Pharmaceuticals Holdings, Inc.","displaySize":"","headline":null,"caption":"Corbus Pharmaceuticals Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z7Iu.c3o3K9KWXFezgFH1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18","width":300,"height":169}},"lazy":false},{"type":"text","content":"NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026.","length":410,"tagName":"p"},{"type":"text","content":"36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern TimeWebcast Link: Click Here","length":212,"tagName":"p"},{"type":"text","content":"About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.","length":818,"tagName":"p"},{"type":"text","content":"INVESTOR CONTACTS:Sean MoranChief Financial OfficerCorbus [email protected]","length":100,"tagName":"p"},{"type":"text","content":"Dan FerryManaging DirectorLifeSci Advisors, LLCda...